Dipraglurant

DB12733InvestigationalSmall molecule

Dipraglurant has been used in trials studying the treatment of Parkinson's Disease. It is a metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator (NAM).

Mechanism: Pharmacologically active on Metabotropic glutamate receptor 5
Curator reviewed
Formula / weight: C₁₆H₁₂FN₃ · 265.291 g/mol (avg)
Code names: ADX-48621

Resolves to

Compound

UNIICV8JZR21A1CAS872363-17-2ChEMBLCHEMBL2346738PubChem44557636

Structure

InChIKeyLZXMUJCJAWVHPZ-UHFFFAOYSA-NSMILESFC1=CN2C=C(CCC#CC3=CC=CC=N3)N=C2C=C1

Targets

P41594GRM5

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Dipraglurant, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account